^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    BTK degrader

    Related drugs:
    5d
    M23-647: Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies (clinicaltrials.gov)
    P1, N=135, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting | N=225 --> 135
    Enrollment closed • Enrollment change • Adverse events • First-in-human
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive
    |
    ABBV-101
    12d
    NX-2127-001: A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=248, Recruiting, Nurix Therapeutics, Inc. | Trial completion date: Dec 2026 --> May 2027 | Trial primary completion date: Dec 2025 --> May 2026
    Trial completion date • Trial primary completion date • First-in-human
    |
    CD4 (CD4 Molecule)
    |
    zelebrudomide (NX-2127)
    14d
    M23-647: Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies (clinicaltrials.gov)
    P1, N=225, Recruiting, AbbVie | N=135 --> 225
    Enrollment change • Adverse events • First-in-human
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive
    |
    ABBV-101
    17d
    M23-647: Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies (clinicaltrials.gov)
    P1, N=135, Recruiting, AbbVie | N=95 --> 135
    Enrollment change • Adverse events • First-in-human
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive
    |
    ABBV-101
    21d
    M23-647: Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies (clinicaltrials.gov)
    P1, N=95, Recruiting, AbbVie | N=44 --> 95
    Enrollment change • Adverse events • First-in-human
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive
    |
    ABBV-101
    28d
    NX-5948-201: A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a Bcell Lymphoma-2 Inhibitor (BCL-2i) (DAYBreak CLL-201) (2025-521088-10-00)
    P1/2, N=41, Recruiting, Nurix Therapeutics Inc.
    New P1/2 trial
    |
    bexobrutideg (NX-5948)
    1m
    A Study of APG-3288 in Relapsed/Refractory Blood Cancers (clinicaltrials.gov)
    P1, N=180, Not yet recruiting, Ascentage Pharma Group Inc.
    New P1 trial
    1m
    BGB-16673-104: A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies (2024-516234-35-00)
    P1/2, N=99, Recruiting, BeOne Medicines AG
    New P1/2 trial
    |
    Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Lunsumio (mosunetuzumab-axgb) • sonrotoclax (BGB-11417) • Columvi (glofitamab-gxbm) • catadegbrutinib (BGB-16673)
    1m
    NX-5948-201: A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a Bcell Lymphoma-2 Inhibitor (BCL-2i) (DAYBreak CLL-201) (2025-521088-10-00)
    P1/2, N=40, Recruiting, Nurix Therapeutics Inc.
    New P1/2 trial
    |
    bexobrutideg (NX-5948)
    1m
    BGB-16673-304: A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. (2025-522860-34-00)
    P2/3, N=196, Recruiting, BeOne Medicines AG
    New P2/3 trial
    |
    Jaypirca (pirtobrutinib) • catadegbrutinib (BGB-16673)
    2ms
    ALLG NHL43: An open-label multi-centre international phase 2 trial to evaluate the safety and efficacy of two years fixed duration therapy with sonrotoclax in combination with the BGB-16673 and rituximab in patients with treatment naïve or BTKi naïve/intolerant Waldenström Macroglobulinemia (WM). (ACTRN12626000174381)
    P2, N=80, Not yet recruiting, Australasian Leukaemia and Lymphoma Group
    New P2 trial
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    Rituxan (rituximab) • sonrotoclax (BGB-11417) • catadegbrutinib (BGB-16673)
    2ms
    Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets (clinicaltrials.gov)
    P1, N=18, Recruiting, Nurix Therapeutics, Inc. | Trial completion date: Dec 2025 --> Aug 2026 | Trial primary completion date: Nov 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    bexobrutideg (NX-5948)